The 2015 News Archive of Autifony Therapeutics: researching treatments for hearing disorders – tinnitus & age related hearing loss - & schizophrenia

2015 News Archive

Autifony Therapeutics initiates Phase I study of AUT00206, a novel treatment approach for schizophrenia

London, UK -  24th November 2015 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing loss and other serious brain disorders, today announced the start of Phase I clinical evaluation of its second Kv3 modulator, AUT00206. This is the first time that a Kv3 modulation mechanism has been applied to the treatment of schizophrenia. AUT00206 represents a novel class of Kv3 modulator which is being developed specifically for schizophrenia and related indications.

 

Read more


Update from Autifony Therapeutics’ QUIET-1 clinical trial

London, UK - 13th October 2015 - Autifony Therapeutics has now completed a planned interim analysis on the QUIET-1 tinnitus clinical trial with AUT00063. This analysis was conducted to check for evidence of treatment efficacy and to ensure that there were no safety or tolerability signals. Following its review of the results from 58 subjects who have completed the QUIET-1 trial, the Independent Data Monitoring Committee recommended that Autifony terminate recruitment due to lack of efficacy. The Committee compared the outcome of the AUT00063-treated subjects with those that received placebo, and concluded that on a statistical basis it would not be possible to reach the magnitude of positive outcome needed to show improvement over the control.

Read more


Dr John Hutchison joins Autifony Therapeutics as Chief Medical Officer

London, UK -  03 September 2015 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that Dr John Hutchison has joined the company as Chief Medical Officer, ahead of the planned retirement of Dr Peter Harris at the end of September.

Read more


Autifony Therapeutics extends Series A with £8 million for hearing disorders and schizophrenia clinical trials

London, UK - 10th July 2015 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced the closing of an £8 million extension to its Series A funding round.

Read more


Autifony Therapeutics recruits first patient into Phase IIa trial for first-in-class drug to treat Age Related Hearing Loss. Study follows acceptance of Autifony’s first IND by the FDA

London, UK – 27th April 2015- Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced that it has recruited the first subject in a Phase IIa study for treatment of Age Related Hearing Loss. This proof of concept study (called CLARITY-1) will explore the potential of AUT00063, Autifony’s first-in-class Kv3 potassium channel modulator, to improve hearing in the elderly by focusing on the discrimination of speech from background noise, which is an area of significant unmet medical need.

Read more


Autifony Therapeutics announces £3.3 million collaboration to progress first-in-class drug for schizophrenia into clinical trials

London, UK – 16th April 2015 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for hearing disorders, today announced a £3.3 million collaborative project to progress its new drug, AUT00206 into clinical trials for the treatment of schizophrenia. £2.4 million will come from the Biomedical Catalyst, jointly funded by Innovate UK and the Medical Research Council. 

Read more